DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2)

Date: March 13, 2020

Time: 8:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications.

Place: Courtyard by Marriott
5520 Wisconsin Avenue
Chevy Chase, MD 20815

Contact Person: Hiromi Ono, Ph.D.
Scientific Review Officer
Office of Extramural Affairs
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Boulevard, Room 4238, MSC 9550
Bethesda, MD 20892
301-402-6020
hiromi.ono@nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.
Name of Committee: National Institute on Drug Abuse Special Emphasis Panel SEP II: Medications Development

Date: March 19, 2020

Time: 1:00 PM to 2:30 PM

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health
Neuroscience Center Building
6001 Executive Boulevard, Room 4236
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Boulevard, Room 4242, MSC 9550
Bethesda, MD 20892
301-827-5833
ivan.navarro@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel NIDA SEP for Medications Development

Date: March 19, 2020

Time: 2:30 PM to 5:00 PM

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health
Neuroscience Center Building
6001 Executive Boulevard, Room 4236
Rockville, MD 20852
(Telephone Conference Call)

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH  
6001 Executive Boulevard, Room 4242, MSC 9550  
Bethesda, MD 20892  
301-827-5833  
ivan.navarro@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Modeling HIV Neuropathology Using Microglia from Human iPSC and Cerebral Organoids (R01 Clinical Trial Not Allowed)

Date: March 25, 2020

Time: 12:00 PM to 4:30 PM

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health  
Neuroscience Center Building  
6001 Executive Boulevard  
Rockville, MD 20852  
(Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
National Institute on Drug Abuse  
National Institutes of Health  
6001 Executive Boulevard, Room 4235 MSC 9550  
Bethesda, MD 20892-9550  
301-827-5819  
gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

Date: March 26, 2020

Time: 8:00 AM to 5:00 PM

Agenda: To review and evaluate grant applications.
Place: Hilton Washington/Rockville
1750 Rockville Pike
Rockville, MD 20852

Contact Person: Ivan K. Navarro, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
6001 Executive Boulevard, Room 4242, MSC 9550
Bethesda, MD 20892
301-827-5833
ivan.navarro@nih.gov


Tyeshia M. Roberson, Program Analyst,
Office of Federal Advisory Committee Policy.
[FR Doc. 2020-04060 Filed: 2/27/2020 8:45 am; Publication Date: 2/28/2020]